Meyer Amends Altamira Therapeutics Filing

TL;DR

Meyer just updated his Altamira Therapeutics filing. Watch this space.

AI Summary

Thomas Meyer filed Amendment No. 13 to Schedule 13D for Altamira Therapeutics Ltd. on March 13, 2024. This filing indicates a change in beneficial ownership, though specific details on the percentage change or new holdings are not provided in this excerpt. The filing relates to Altamira Therapeutics Ltd., formerly known as Auris Medical Holding Ltd.

Why It Matters

This amendment signals a potential shift in significant ownership stakes, which could influence the company's stock performance and strategic direction.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate significant shifts in control or investment strategy, potentially impacting stock price.

Key Players & Entities

• Thomas Meyer (person) — Filing party and authorized contact
• Altamira Therapeutics Ltd. (company) — Subject company
• Auris Medical Holding Ltd. (company) — Former name of subject company
• March 13, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.002 — me of Issuer) Common Stock, par value $0.002 per share (Title of Class of Securiti
• $3.24 — 51 Common Shares at a purchase price of $3.24 per share for a total of $165.24. The R
• $165.24 — price of $3.24 per share for a total of $165.24. The Reporting Person purchased these C
• $1.864 — 50 Common Shares at a purchase price of $1.864 per share for a total of $32,337.84. Th
• $32,337.84 — rice of $1.864 per share for a total of $32,337.84. The Reporting Person purchased these C

Filing Documents

• ea0201723-13da13meyer_altami.htm (SC 13D/A) — 33KB
• 0001213900-24-022034.txt ( ) — 34KB

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration

of the Schedule 13D

Item 3 of the Schedule 13D is hereby supplemented by adding the following: On December 29, 2023, the Reporting Person purchased 51 Common Shares at a purchase price of $3.24 per share for a total of $165.24. The Reporting Person purchased these Common Shares with personal funds. On March 11, 2024, the Reporting Person purchased 17,350 Common Shares at a purchase price of $1.864 per share for a total of $32,337.84. The Reporting Person purchased these Common Shares with personal funds. Item 5. Interest in Securities of the Issuer

of the Schedule 13D

Item 5 of the Schedule 13D is hereby amended by deleting it in its entirety and substituting the following in lieu thereof: (a) The information contained on the cover pages to the Schedule 13D is incorporated by reference herein. As of the date hereof, there are 1,837,845 Common Shares outstanding. The Reporting Person beneficially owns 22,297 Common Shares including Common Shares that the Reporting Person has the right to acquire within sixty (60) days of the date hereof upon exercise of outstanding options and warrants, representing 1.2% of the class. (b) The Reporting Person holds sole power to vote and dispose over all of the Common Shares of the Issuer that he beneficially owns. (c) The information provided in Item 3 and Item 4 of the Schedule 13D is incorporated by reference herein. Except as described herein, during the past sixty (60) days on or prior to March 17, 2024 (the “ Event Date ”), and from the Event Date to the date hereof, there were no other purchases or sales of Common Shares, or securities convertible into or exchangeable for Common Shares, by the Reporting Person or any person or entity for which the Reporting Person possesses voting or dispositive control over the securities thereof. (d) Not applicable. (e) Not applicable. 3 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 13, 2024 /s/ Thomas Meyer Thomas Meyer Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). 4

View Full Filing

View this SC 13D/A filing on SEC EDGAR